DBV Technologies S.A. (DBVT) Upgraded by Zacks Investment Research to Buy
DBV Technologies S.A. (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $32.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 18.43% from the company’s current price.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Several other analysts have also recently weighed in on DBVT. Societe Generale cut shares of DBV Technologies from a “buy” rating to a “sell” rating in a report on Tuesday. BidaskClub cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, August 11th. ValuEngine upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Barclays PLC cut their price target on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Citigroup Inc. lifted their price target on shares of DBV Technologies from $43.00 to $57.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $49.63.
DBV Technologies (NASDAQ DBVT) traded down 4.59% during midday trading on Tuesday, reaching $27.02. 3,040,271 shares of the company’s stock were exchanged. The stock’s market cap is $1.24 billion. The firm has a 50 day moving average of $44.48 and a 200-day moving average of $39.50. DBV Technologies has a 12 month low of $22.33 and a 12 month high of $50.57.
A number of large investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new position in DBV Technologies during the second quarter valued at $222,000. Victory Capital Management Inc. purchased a new position in DBV Technologies during the first quarter valued at $303,000. Airain ltd purchased a new position in DBV Technologies during the second quarter valued at $333,000. Sit Investment Associates Inc. purchased a new position in DBV Technologies during the second quarter valued at $698,000. Finally, Jane Street Group LLC purchased a new position in DBV Technologies during the first quarter valued at $853,000. Institutional investors and hedge funds own 45.52% of the company’s stock.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.